Neuropace, Inc. Common Stock

Day range

$12.64 – $13.22

Open

$12.90

Prev close

$12.91

Volume

67.31K

Market cap

$443.13M

Shares out

34.32M

P/E

—

P/S

4.48

P/B

37.29

P/FCF

—

ROE

-160.8%

ROA

-19.7%

Debt/Equity

4.97

Div yield

0.00%

As of Oct 23, 2026

• Regulatory decisionJul 28, 2026

  the Company issued a press release announcing that it had received notification from the U.S. Food and Drug Administration (FDA) that its Premarket Approval Supplement (PMA-S) seeking to expand the labeled indication for the RNS System to include patients with antiseizure medication-resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic (GTC) seizures is not approvable in its current form and that additional clinical evidence supporting the submission has been requested.

• Executive compensation changeJun 24, 2025

  Pursuant to the terms of the Offer Letter and Employment Agreement (the "Offer Letter"), between Mr. Williams and the Company, Mr. Williams's base salary will be $500,000 per year and his annual target bonus will be 60% of his base salary. Bonus amounts will be determined based upon achievement of goals agreed upon with the Board of Directors. Pursuant to the Offer letter, Mr. Williams will be granted sign-on equity awards in the form of restricted stock units representing 10,370 shares of the Company's common stock and stock options to purchase 17,600 shares of the Company's common stock with an exercise price equal to the fair market value on the date of the grant (collectively, the "Sign-on Awards"). Mr. Williams will also receive a new hire equity award in the form of restricted stock units representing 41,480 shares of the Company's common stock and stock options to purchase 70,350 shares of the Company's common stock with an exercise price equal to the fair market value on the date of the grant (the "New Hire Awards" and collectively with the Sign-on Awards, the "Equity Awards").

• Deal terminationJun 4, 2025

  On June 4, 2025, concurrently with the Company's entry into the Credit Agreement described in Item 1.01 hereof, the Company terminated its existing Term Loan Agreement, dated as of September 24, 2020 (as amended by that certain First Amendment to Term Loan Agreement, dated as of March 8, 2022, that certain Second Amendment to Term Loan Agreement, dated as of February 28, 2023, that certain Third Amendment to Term Loan Agreement, dated as of May 2, 2024, and as further amended, restated, modified, or otherwise supplemented from time to time, the "Existing Loan Agreement").

• Guidance issuance or updateMay 27, 2025

  On May 27, 2025, NeuroPace, Inc. (the "Company) issued a press release announcing, among other matters, the reaffirming of guidance for fiscal year 2025.

• Business updateApr 14, 2025

  NeuroPace, Inc. (the "Company") issued a press release announcing that it anticipates minimal impact from the international trade tariffs on its operations and financial results.

Days to cover

6.2

Short interest

903.63K

Avg volume

146.3K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight
  positiveGlobeNewswire Inc.· Oct 6, 2026
• Why NeuroPace Stock Was Inching Higher on Wednesday
  positiveThe Motley Fool· Mar 4, 2026
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
  negativeGlobeNewswire Inc.· May 28, 2025
• UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference
  positiveGlobeNewswire Inc.· Mar 3, 2025
• Neuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S Insider
  positiveGlobeNewswire Inc.· Nov 11, 2024